Standard Glass Lining Technology burst onto the trading floor with a flourish, listing at ₹172 on the NSE—a healthy 22.8% above its ₹140 issue price. Over on the BSE, it went a notch higher, debuting at ₹176, marking a 25.71% premium. For a company born in 2012 and laser-focused on serving India’s pharmaceutical and chemical industries, this IPO success feels like a well-deserved nod to its niche expertise. The IPO, which raked in ₹410 crore, turned out to be a crowd-puller. With bids stacking up 185.48 times the shares on offer, it wasn’t just a subscription; it was a stampede. Retail investors pitched in 65.71 times over their quota, and big-pocketed non-institutional buyers went all in with 275.21 times oversubscription. Qualified Institutional Buyers, who lined up with bids 327.76 times the allocation, underlining serious market confidence. A significant chunk of proceeds is earmarked for machinery and tech upgrades, aiming to sharpen operational efficiency. Another slice of the pie is heading toward debt reduction, including a cleanup of its subsidiary S2 Engineering’s financial slate. There’s also a forward-thinking plan to fund acquisitions and expand its global footprint, a leap from its current export revenue of 0.5% to an ambitious 20% by 2026. The financials don’t just look rosy—they shine. Analysts are optimistic, predicting a 20-25% revenue CAGR in the medium term, fueled by geographical and product diversification. Compared to its peers, Standard Glass boasts a premium margin profile, making its IPO valuation look grounded.